晚期非小细胞肺癌中ERCC1、β-tubulin3及TOPOⅡ的表达与临床病理特征及铂类化疗疗效的关系  

Expression of ERCC1,β-tubulin 3 and TOPO Ⅱ in advanced non-small-cell lung cancer and their relationship with clinical pathological features and efficacy of platinum based chemotherapy

作　　者：张春节[1] 姜维美[2] 韩磊[1] 孙咏梅[1] 

机构地区：[1]江苏省连云港市第二人民医院病理科,江苏连云港222000 [2]江苏省连云港市第二人民医院肿瘤科,江苏连云港222000

出　　处：《中国当代医药》2016年第35期7-10,共4页China Modern Medicine

基　　金：江苏省连云港市卫生计生委科研项目(1319)

摘　　要：目的 探讨ERCC1、β-tubulin 3及TOPOⅡ在晚期非小细胞肺癌（NSCLC）中的表达与临床病理特征及与铂类化疗疗效的关系。方法 选取2012年1月-2013年6月在我院治疗的61例晚期NSCLC住院患者作为研究对象,采用免疫组化方法检测其组织中ERCC1、β-tubulin 3及TOPOⅡ的表达,患者均接受培美曲塞联合奈达铂方案化疗并定期评价疗效。结果 ERCC1、β-tubulin 3的表达与患者的年龄、性别、临床分期及组织学类型均无关（P〉0.05）;TOPOⅡ的表达与患者的年龄、性别、临床分期无关（P〉0.05）;TOPOⅡ在腺癌中阳性表达8例（22.86%）,鳞癌阳性表达14例（53.85%）,鳞癌的表达高于腺癌,差异有统计学意义（P=0.017）。ERCC1、β-tubulin 3及TOPOⅡ的阳性表达分别为40.98%（25/61）、47.54%（29/61）及36.66%（22/61）,阳性表达化疗有效率分别为16.00%（4/25）、48.28%（14/29）及63.64%（14/22）,阴性表达化疗有效率分别为63.89%（23/36）、40.63%（13/32）及33.33%（13/39）。结论 ERCCI及TOPOⅡ阳性可预测NSCLC对铂类化疗药物的疗效,且TOPOⅡ对不同组织学类型的晚期非小细胞肺癌疗效预测具有重要意义。Objective To explore the expressions of ERCC1,β-tubulin 3 and TOPO Ⅱ in advanced non-small-cell lung cancer （NSCLC） and their correlations with clinical pathological features and efficacy of platinum based chemotherapy. Methods 61 patients with NSCLC in our hospital from January 2012 to June 2013 were selected as the study subjects, mmunohistochemieal method was used to detect the expression of tissue ERCC1 and β-tubulin 3 and TOPO Ⅱ ,All the patientswere treated with Pemetrexed combined with Nedaplatin chemotherapy,and the efficacy was evaluated on a regular.Results The express of ERCC1 and β-tubulin 3 was not related to the age,sex,clinical stage and histological type of the patient （P〉0.05）.The expression of TOPO Ⅱ was not related to the age,sex,and clinical stage of the patients （P〉0.05）.The positive expression of TOPO Ⅱ in adenoeareinoma was 8 cases （22.86%）,14 cases （53.85%） were positive in squamous cell carcinoma,and the positive expression of ERCC1,β-tubulin 3 and TOPO Ⅱ in squamous cell carcinoma was higher than that in adenoearcinoma,with significant difference （P=0.017）.The positive expression of ERCC 1, β-tubulin 3 and TOPO Ⅱ were 40.98% （25/61）,47.54% （29/61） and 36.66% （22/61） respectively,the effective rate of positive expression of chemotherapy was 16.00% （4/25）,48.28% （14/29） and 63.64% （14/22）,the effective rate of negative expression of chemotherapy was 63.89% （23/36）,40.63% （13/32） and 33.33% （13/39）.Conclusion The positive expression of ERCCI and TOPO Ⅱ can predict the efficacy of NSCLC in the treatment of platinum based chemotherapy drugs,and TOPO Ⅱ has important significance for the prognosis of advanced NSCLC with different histological types.

关 键 词：非小细胞肺癌 ERCC1 Β-TUBULIN 3 TOPOⅡ 免疫组化 

分 类 号：R734.2[医药卫生—肿瘤]